Escend Pharmaceuticals, Inc., Receives IND Clearance from the FDA for ES-3000 Phase I Study in Relapsed or Refractory Acute Myeloid Leukemia (AML)
2022-07-15
合作孤儿药小分子药物
Escend announces IND clearance for ES-3000 phase I study in relapsed or refractory (R/R) acute myeloid leukemia (AML)
MENLO PARK, Calif., July 15, 2022 /PRNewswire/ -- Escend Pharmaceuticals, Inc., a privately held company focused on the development of small molecule therapeutics for oncology orphan diseases, announced today that the United States Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for its lead drug candidate, ES-3000 for a Phase I clinical trial in relapsed or refractory (R/R) acute myeloid leukemia (AML).
The primary aim of the Phase I study is to determine the safety and tolerability of ES-3000 in subjects with R/R AML. The FDA Office of Orphan Products Development has previously granted ES-3000 orphan designation for the treatment of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The FDA orphan drug designation provides 7 years of marketing exclusivity and certain incentives, including federal grants, tax credits, and waiver of new drug application (NDA) fees.
"The IND clearance strengthens our deep commitment to the development of ES-3000, which can potentially offer a new treatment option for durable remissions and reduce relapse by targeting leukemic stem cells, which play a central role in resistance to therapy", said Saira Bates, MBA, Co-founder & CEO. "We are very excited to be able to initiate our US study. ES-3000 is a novel small molecule with promising pre-clinical data that supports targeting leukemic stem cells." said Dennis Brown, PhD, Co-founder & Chairman.
About ES-3000
ES-3000 is an orally bioavailable small molecule which ablates leukemic stem cells by reducing β-catenin expression through a novel mechanism of action. The Wnt/β-catenin pathway is critical for the survival of cancer stem cells. ES-3000 is also in development for the treatment of chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), and triple negative breast cancer (TNBC).
About Escend
Escend's development strategy is to select drug candidates with established clinical safety that have not yet achieved US marketing approval and match them to oncology orphan indications, where their effects on specific cellular pathways can be leveraged for the development of novel therapeutics.
SOURCE Escend Pharmaceuticals, Inc.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。